Dear Partners,

A Very Good Afternoon to all of you. The Industry witnessed a high double
digit growths giving rise to a question has ache din come for the Pharma
Markets.
Key Insights for February 2015:
1. IPM after clocking double digits for the last 3 months, powered itself
highest growth of 18.9%, which is the highest in last 19 months of the IPM

2. For Month of Feb-15, we have seen the GDs as 10.1% in Volumes,

5.6% in Price Increases & 3.2% in NIs against a -0.2% in volumes & 1.5%
in Price Increases in Feb-14

3. Price Increase was at 5.6% , the highest in the last 19 months and an
running quarter average of 5.2% coming from price increases

4. There has been a growth registered (15.1%) in this quarter which is

higher than the corresponding Quarter last year (8.8%)

5. Whether the sudden increase can also be attributable to the external

environment especially due to the H1N1 situation is a thing to be
evaluated on

Major Highlights for Month of February 2015:

February Month Highlights:
The IPM clocked 7194 Crs in February 2015
The Indian Pharma Market grows at 18.9% for the month of February 2015

 Corporate:
For the month of February 2015, amongst the top 10, Cipla grew by 24.0%
followed by Lupin at 23.2% & Pfizer at 22.6%
22 corporate have crossed the growth of IPM for the month of February
2015 amongst top 50
Amongst the top 50 Corporate, Akumentis has the highest growth of
52.5% followed by Macleods at 39.4% & JBCPL at 38.0 %
45 Corporate showed growths more than 10% amongst the top 50
Amongst the 11-20 ranked Corporate Macleods has the highest growth of
39.4% followed by Glenmark at 33.3% & Torrent at 30.8%
Amongst the 51-60 ranked Corporate, Centaur grew at 33.4% followed by
Allergan at 30.0% & Wanbury at 24.3%
Amongst the 61-70 ranked Corporate, Boehringer grew by 88.5% followed
by TTK at 31.2% & Tablets India at 30.0%

Indian V/S MNCs:

Indian companies have grown at 19.4% versus 17.6% for MNCs in
February 2015
Amongst the top 50 in MNCs Merck grew by 32.2% followed by Sanofi at
30.7% & MSD at 24.5%
Under the Non-NLEM category Indian Companies grew at 20.8% whereas
MNCs grew at 17.7%

DPCO, Non DPCO & Non-Scheduled Para 19 Market:

The DPCO containing molecules market grew at 13.9 % whereas the non
DPCO market grew by 20.0% & Non -Sch Para 19 Market at 14.4% resulting
in an overall growth of 18.9% for February 2015

 NLEM & Non - NLEM Category showed unit growth at 7.6% and 10.1%
respectively. The Non-Sch Para 19 Market grew at 9.9% from units
perspective
The DPCO 2013 portfolio for Pfizer grew at 21.1%, Ranbaxy 20.7% &
Abbott 18.3%

Therapy:
From therapy perspective 9 therapies have outgrown the IPM growth & 18
therapies have double digit growths
Respiratory Market grew at 25.4%, Gastrointestinal market grew at
19.1% , Pain & Analgesics market grew at 15.7% whereas Anti-infectives
grew at 19.6%
Anti-diabetic market grows at 32.7% & Cardiac at 16.6% in chronic
business
Derma market grew by 18.0% & Urology Market at 26.7%

Regional Dynamics:
From regional perspective 16 regions have outgrown the IPM growth
Madhya Pradesh market grew the highest at 28.8% followed by South
Rajasthan market at 27.0% & Telangana Market at 26.3%
No regions had negative growth in February 2015

Molecules:
Amoxycillin + Clavulanic Acid Market grew at 24.7% whereas Glimepiride
+ Metformin grows at 17.2% at No 2.
The markets of Paracetamol grew at 28.9%, Atorvastatin 17.2%, Probiotic
Microbes at 19.6%, Cefixime 21.3%, Pantoprazole 20.1%, Montelukast +
Levocetrizine at 33.5%, Glimepiride + Metformin + Pioglitazone at 31.3%,
Vitamin-D at 37.3%, Hydroquinone + Mometasone + Tretinoin at 10.6%,

Voglibose + Metformin + Glimepiride at 60.2%, Rosuvastatin at 26.9%,

Protein Supplements at 23.0%

Brands:
Mixtard continues to lead the pack with 38 Crs for the Month of Feb -15
Glycomet-GP grew at 23.6%, Augmentin at 24.0%, Monocef at 23.5%,
Dexorange at 21.4% & Lantus at 32.9% amongst the top 10 Brands
Few Brands who have gained ranks include Pentaxim (+171), Januvia
(+69), Janumet (+67), Shelcal (+54), Magnex (+52), Clexane (+50),
Panderm Plus (+46), Jalra M (+43), Istamet (+40), Monocef O (+27), Dolo
(+23), Rosuvas (+19), Udilive & Tonact (+18), Pan D (+15), Taxim (+8), Pan
(+3), Sinarest (+2) amongst top 100 Brands over Feb -14

New Launches in IPM:

Total 144 Brands launched in February 2015
Top New Brands for February are Materna, Rosuvas CV & Dienofem

Therapy Perspective:

PS: We have revalidation of GSK Vaccine Business & Medo Pharm in this database

We are glad to share that from current month onwards we have

added 7 new regions to make 30 overall Regions in our PharmaTrac
Audit. It is our commitment to transform this audit in F16 financial
year from Regional Audit (relevant only to Regional Managers &
Above) to Area Audit (relevant to a team of 40 odd Area Managers)
by continuing this journey of bifurcating into smaller regions. Some
large Regions we have still not be able to bifurcate due to
inadequate panel (as we go smaller geographies, proportion of data
needs to increase for statistical stability). The journey is on and

panel addition is happening on the ground so that we end F16 with

40 regions.
The endeavor is to involve Area Managers (and upwards) and
sensitize them about the local competition and opportunities to
drive growth.
Old Region
ANDHRA PRADESH
ANDHRA PRADESH
TELANGANA
GUJARAT
GUJARAT
GUJARAT
MARATHWADA
MARATHWADA
VIDARBHA
MUMBAI
MUMBAI
RAJASTHAN
RAJASTHAN

New Region
NORTH AP
SOUTH AP
TELANGANA
NORTH GUJARAT
SAURASHTRA
SOUTH GUJARAT
N MAHARASHTRA
S MAHARASHTRA
VIDARBHA
MUMBAI CITY
OUTER MUMBAI
N RAJASTHAN
S RAJASTHAN

ownership: Public Independent